{
    "root": "30b471d8-c5ab-9007-e063-6394a90ac8e9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine Hydrochloride",
    "value": "20250319",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV"
        }
    ],
    "indications": "phentermine hydrochloride tablets indicated short-term ( weeks ) adjunct regimen weight reduction based exercise , behavioral modification caloric restriction management exogenous obesity patients initial body mass index ≥ 30 kg/m 2 , ≥ 27 kg/m 2in presence risk factors ( e.g . , controlled hypertension , diabetes , hyperlipidemia ) . chart body mass index ( bmi ) based various heights weights . bmi calculated taking patient 's weight , kilograms ( kg ) , divided patient 's height , meters ( ) , squared . metric conversions follows : pounds ÷ 2.2 = kg ; inches × 0.0254 = meters . body mass index ( bmi ) , kg/m 2 weight ( pounds ) height ( feet , inches ) 5 ' 0 `` 5 ' 3 `` 5 ' 6 `` 5 ' 9 `` 6 ' 0 `` 6 ' 3 `` 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 limited usefulness agents class , including phentermine , [ pharmacology ( 12.1 , 12.2 ) ] measured possible risk factors inherent described .",
    "contraindications": "individualized obtain adequate response lowest effective dose . ( 2.1 ) late evening avoided ( risk insomnia ) . ( 2.1 ) phentermine hydrochloride tablets taken without food . ( 2.1 ) limit 15 mg daily patients severe renal impairment ( egfr 15 29 ml/min/1.73 2 ) ( 2.2 )",
    "warningsAndPrecautions": "phentermine hydrochloride tablets , usp 37.5 mg white blue speckles , capsule-shaped tablets , bisected debossed `` є `` left bisect `` 16 `` right bisect one side , plain side . tablets packaged bottles 100 ( ndc 68071-3808-1 ) .",
    "adverseReactions": "history cardiovascular disease ( e.g . , coronary artery disease , stroke , arrhythmias , congestive heart failure , uncontrolled hypertension ) within 14 days following monoamine oxidase inhibitors hyperthyroidism glaucoma agitated states history abuse pregnancy [ ( 8.1 ) ] nursing [ ( 8.3 ) ] known hypersensitivity , idiosyncrasy sympathomimetic amines",
    "indications_original": "Phentermine hydrochloride Tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m\n \n  2, or ≥ 27 kg/m\n \n  2in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n\n \n                  Below is a chart of body mass index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters.\n                  \n                     BODY MASS INDEX (BMI), kg/m\n  \n   2\n                     \n                     \n                     \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           Weight (pounds)\n                           Height (feet, inches)\n                        \n                        \n                           5'0\"\n                           5'3\"\n                           5'6\"\n                           5'9\"\n                           6'0\"\n                           6'3\"\n                        \n                     \n                     \n                        \n                           140\n                           27\n                           25\n                           23\n                           21\n                           19\n                           18\n                        \n                        \n                           150\n                           29\n                           27\n                           24\n                           22\n                           20\n                           19\n                        \n                        \n                           160\n                           31\n                           28\n                           26\n                           24\n                           22\n                           20\n                        \n                        \n                           170\n                           33\n                           30\n                           28\n                           25\n                           23\n                           21\n                        \n                        \n                           180\n                           35\n                           32\n                           29\n                           27\n                           25\n                           23\n                        \n                        \n                           190\n                           37\n                           34\n                           31\n                           28\n                           26\n                           24\n                        \n                        \n                           200\n                           39\n                           36\n                           32\n                           30\n                           27\n                           25\n                        \n                        \n                           210\n                           41\n                           37\n                           34\n                           31\n                           29\n                           26\n                        \n                        \n                           220\n                           43\n                           39\n                           36\n                           33\n                           30\n                           28\n                        \n                        \n                           230\n                           45\n                           41\n                           37\n                           34\n                           31\n                           29\n                        \n                     \n                  \n                  The limited usefulness of agents of this class, including phentermine, [\n \n  see\n  \n   Clinical Pharmacology (12.1,\n  \n   12.2)\n                     ] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications_original": "Dosage should be individualized to obtain an adequate response with the lowest effective dose. ( 2.1 ) Late evening administration should be avoided (risk of insomnia). ( 2.1 ) Phentermine Hydrochloride Tablets can be taken with or without food. ( 2.1 ) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ) ( 2.2 )",
    "warningsAndPrecautions_original": "Phentermine Hydrochloride Tablets, USP 37.5 mg are white with blue speckles, capsule-shaped tablets, bisected and debossed with \"Є\" to the left of bisect and \"16\" to the right of bisect on one side, and plain on the other side.\n                  Tablets are packaged in bottles of 100 (NDC 68071-3808-1).",
    "adverseReactions_original": "History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\n                     During or within 14 days following the administration of monoamine oxidase inhibitors\n                     Hyperthyroidism\n                     Glaucoma\n                     Agitated states\n                     History of drug abuse\n                     Pregnancy [\n  \n   see\n   \n    Use in Specific Populations (8.1)\n                        ]\n \n  \n                     Nursing [\n  \n   see\n   \n    Use in Specific Populations (8.3)\n                        ]\n \n  \n                     Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines"
}